Merck Accelerates Drug-Submission Plans

Merck has accelerated its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval, in a bid to close the gap with competitors in two lucrative segments.



from WSJ.com: US Business http://ift.tt/1B8hAoH

via IFTTT